Open Access

Artesunate and cisplatin synergistically inhibit HNSCC cell growth and promote apoptosis with artesunate‑induced decreases in Rb and phosphorylated Rb levels

  • Authors:
    • Hiroki Okamoto
    • Kazuhiro Yoshikawa
    • Akiko Shimada
    • Rui Sano
    • Daisuke Inukai
    • Shunpei Yamanaka
    • Susumu Suzuki
    • Ryuzo Ueda
    • Hiromi Ueda
    • Yasushi Fujimoto
    • Tetsuya Ogawa
  • View Affiliations

  • Published online on: June 19, 2023     https://doi.org/10.3892/or.2023.8591
  • Article Number: 154
  • Copyright: © Okamoto et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

In the treatment of head and neck cancer, cisplatin is often used as a therapeutic agent; however, its efficacy is limited and it can cause renal dysfunction as an adverse effect. For this reason, the use of cisplatin is limited in elderly patients with reduced renal function. Recently, artemisinin, which was developed as an antimalarial drug, was found to have antitumor effects and is effective in combination with other anticancer drugs. In the present study, the antitumor effects of artemisinin and its derivatives as well as their combination with cisplatin and iron on head and neck squamous cell carcinoma cell lines, were investigated. Cell viability was determined by a cell viability assay, the cell cycle was analyzed by flow cytometry, cell death was assessed with annexin V and propidium iodide staining, and western blotting was used to analyze retinoblastoma protein (Rb), phosphorylated (p‑)Rb, and other cell cycle‑associated molecules. A total of four artemisinin compounds were examined and it was found that artesunate and dihydroartemisinin had a significant inhibitory effect on growth. It was also identified that the combination of artesunate, cisplatin, and iron inhibited cell proliferation and caused S/G2‑M cell cycle arrest. In addition, western blotting of Rb, a molecule involved in the cell cycle, showed that artesunate induced the loss of not only Rb but also p‑Rb. These results suggested that artesunate is a useful drug in combination with cisplatin.
View Figures
View References

Related Articles

Journal Cover

August-2023
Volume 50 Issue 2

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Okamoto H, Yoshikawa K, Shimada A, Sano R, Inukai D, Yamanaka S, Suzuki S, Ueda R, Ueda H, Fujimoto Y, Fujimoto Y, et al: Artesunate and cisplatin synergistically inhibit HNSCC cell growth and promote apoptosis with artesunate‑induced decreases in Rb and phosphorylated Rb levels. Oncol Rep 50: 154, 2023.
APA
Okamoto, H., Yoshikawa, K., Shimada, A., Sano, R., Inukai, D., Yamanaka, S. ... Ogawa, T. (2023). Artesunate and cisplatin synergistically inhibit HNSCC cell growth and promote apoptosis with artesunate‑induced decreases in Rb and phosphorylated Rb levels. Oncology Reports, 50, 154. https://doi.org/10.3892/or.2023.8591
MLA
Okamoto, H., Yoshikawa, K., Shimada, A., Sano, R., Inukai, D., Yamanaka, S., Suzuki, S., Ueda, R., Ueda, H., Fujimoto, Y., Ogawa, T."Artesunate and cisplatin synergistically inhibit HNSCC cell growth and promote apoptosis with artesunate‑induced decreases in Rb and phosphorylated Rb levels". Oncology Reports 50.2 (2023): 154.
Chicago
Okamoto, H., Yoshikawa, K., Shimada, A., Sano, R., Inukai, D., Yamanaka, S., Suzuki, S., Ueda, R., Ueda, H., Fujimoto, Y., Ogawa, T."Artesunate and cisplatin synergistically inhibit HNSCC cell growth and promote apoptosis with artesunate‑induced decreases in Rb and phosphorylated Rb levels". Oncology Reports 50, no. 2 (2023): 154. https://doi.org/10.3892/or.2023.8591